RxDoctor Payments Data

Carla Dicenzo-Flynn, MD

Internal Medicine · Morristown, NJNPI 1114942075

Payments from drug & device makers

$425in general payments, 2019–2025

Across 13 payments — averaging $32.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$273
  • Eisai Inc.$55
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$28
  • Fresenius Kabi USA, LLC$24
  • Lilly USA, LLC$19
  • Shire North American Group Inc$14
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$39593%
  • Education$307%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$425 in reported general payments places this provider in the 50th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$88,847
Medicare patients
120
Services billed
674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase24$95,029
OzempicSemaglutide48$50,803
MounjaroTirzepatide37$46,701
WegovySemaglutide14$18,797
ViberziEluxadoline11$17,074
Sucralfate13$8,540
Sodium Chloride0.9 % Sodium Chloride53$2,554
Pantoprazole Sodium54$1,996
Diphenhydramine Hcl41$1,124
Ondansetron HclOndansetron Hcl/Pf70$1,120
Gabapentin17$788
Lactated RingersRinger's Solution,lactated41$560
FamotidineFamotidine/Pf93$503
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine11$492
Sodium ChlorideSodium Chloride 0.45 %12$270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$273$69,60062 claims
Lilly USA, LLCMounjaro$19$46,70137 claims
Fresenius Kabi USA, LLCSodium Chloride, Sodium Chloride$24$2,82465 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Morristown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →